LYEL Lyell Immunopharma Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: LYEL

Price (delayed)

$12.63

Market cap

$294.71M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$13.8

Enterprise value

$241.84M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 34
Highlights
The EPS rose by 45% year-on-year and by 14% since the previous quarter
The net income rose by 26% year-on-year and by 10% since the previous quarter
LYEL's quick ratio is up by 37% since the previous quarter but it is down by 6% year-on-year
Lyell Immunopharma's equity has decreased by 19% YoY but it has increased by 10% from the previous quarter
The revenue has dropped by 50% year-on-year and by 19% since the previous quarter
The gross profit has plunged by 50% YoY and by 19% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of LYEL

LYEL stock price

How has the Lyell Immunopharma stock price performed over time
Intraday
-1.17%
1 week
-5.18%
1 month
-2.85%
1 year
21.33%
YTD
-58.97%
QTD
-10.11%

Financial performance

How have Lyell Immunopharma's revenue and profit performed over time
Revenue
$29,000
Gross profit
$29,000
Operating income
-$256.3M
Net income
-$246.41M
Gross margin
100%
Net margin
-849,675.9%
The revenue has dropped by 50% year-on-year and by 19% since the previous quarter
The gross profit has plunged by 50% YoY and by 19% from the previous quarter
Lyell Immunopharma's net margin has decreased by 47% YoY and by 11% QoQ
The operating margin has declined by 42% year-on-year and by 18% since the previous quarter

Price vs fundamentals

How does LYEL's price correlate with its fundamentals

Growth

What is Lyell Immunopharma's growth rate over time

Valuation

What is Lyell Immunopharma stock price valuation
P/E
N/A
P/B
0.98
P/S
9,527.38
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8,339.33
The EPS rose by 45% year-on-year and by 14% since the previous quarter
The stock's P/B is 30% less than its last 4 quarters average of 1.4 and 25% less than its 5-year quarterly average of 1.3
Lyell Immunopharma's equity has decreased by 19% YoY but it has increased by 10% from the previous quarter
LYEL's price to sales (P/S) is 149% more than its 5-year quarterly average of 3829.5 but 7% less than its last 4 quarters average of 10234.9
The revenue has dropped by 50% year-on-year and by 19% since the previous quarter

Efficiency

How efficient is Lyell Immunopharma business performance
The return on sales has declined by 47% year-on-year and by 11% since the previous quarter
Lyell Immunopharma's ROIC has decreased by 17% YoY but it has increased by 6% from the previous quarter
The ROE has contracted by 16% YoY but it has grown by 5% from the previous quarter
The ROA is down by 9% year-on-year but it is up by 5% since the previous quarter

Dividends

What is LYEL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LYEL.

Financial health

How did Lyell Immunopharma financials performed over time
The current ratio rose by 37% since the previous quarter but it has declined by 3.5% year-on-year
LYEL's quick ratio is up by 37% since the previous quarter but it is down by 6% year-on-year
Lyell Immunopharma's debt is 86% lower than its equity
Lyell Immunopharma's debt has decreased by 19% YoY and by 6% QoQ
Lyell Immunopharma's equity has decreased by 19% YoY but it has increased by 10% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.